Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (Nasdaq: SLDB) is set to release its first quarter 2022 financial results on April 27, 2022, before market opening. A conference call will follow at 8:00 a.m. ET to discuss results and updates on the SGT-001 and SGT-003 pipeline programs targeting Duchenne muscular dystrophy. The call will be accessible via a live webcast on the company’s website and through dial-in options for participants.

Solid Biosciences (Nasdaq: SLDB) reported positive two-year efficacy and safety data from the high dose cohort (2E14 vg/kg) of its IGNITE DMD Phase I/II clinical trial, showing sustained or improved motor and pulmonary function in patients treated with SGT-001. The company also noted positive 90-day biopsy results indicating microdystrophin expression consistent with prior patients. Financially, Solid ended 2021 with $207.8 million in cash, funding operations into Q3 2023. Collaboration revenue reached $13.6 million for 2021, up from zero in 2020.

Solid Biosciences (Nasdaq: SLDB) announced participation in a fireside chat at the 11th Annual Global Healthcare Conference on February 17, 2022, at 4:20 pm ET. The chat will feature Joel Schneider, PhD, COO, and Carl Morris, PhD, CSO.

A live webcast will be accessible on the company's investor relations website. Solid Biosciences aims to develop transformative treatments for Duchenne muscular dystrophy, focusing on correcting the underlying mutation with gene therapy candidates SGT-001 and SGT-003.

Solid Biosciences (Nasdaq: SLDB) has announced significant advancements in its Duchenne muscular dystrophy (DMD) programs. The company plans to dose more patients in the IGNITE DMD Phase I/II clinical trial for its gene therapy SGT-001 and aims to submit an IND for the next-generation therapy SGT-003 in early 2023. Additionally, Solid ends 2021 with approximately $210 million in cash and investments. Ian F. Smith, previously Chair of the Board, will assume the role of Executive Chair to support the company’s strategic initiatives.

Solid Biosciences (Nasdaq: SLDB), a company dedicated to therapies for Duchenne muscular dystrophy, announced that CEO Ilan Ganot will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:00 am ET. A Q&A session will follow the presentation. Institutional investors can book meetings with management through their J.P. Morgan representatives. A live webcast will be available on the company’s Investors page, along with an archived replay for 30 days.

Solid Biosciences (Nasdaq: SLDB) announced inducement awards for its new Senior VP of Human Resources, Allison Bogosian. The board approved the grants on November 18, 2021, to incentivize her employment under Nasdaq rules. The inducement includes an option for 131,400 shares at an exercise price of $1.78, alongside a restricted stock unit award for 65,700 shares. Both awards vest in four equal annual installments over four years, contingent on Bogosian's continued service.

Solid Biosciences (SLDB) reported significant progress in its Duchenne muscular dystrophy (Duchenne) therapies during Q3 2021. They announced plans to dose more patients with SGT-001 in the IGNITE DMD trial starting Q4 2021. Financially, the company ended Q3 with approximately $229.8 million in cash, ensuring a runway into Q2 2023. Collaboration revenue rose to $3.5 million, compared to none last year, while R&D expenses decreased to $14.4 million. The net loss narrowed to $18 million from $21.2 million in 2020, indicating improved fiscal management.

The Pathway Development Consortium (PDC), initiated by REGENXBIO and Solid Biosciences, released a draft white paper outlining a framework for the accelerated approval of AAV gene therapies. This initiative aims to unite stakeholders to expedite the development of effective treatments for rare diseases. The publication coincides with the PDC's formal launch, emphasizing collaboration among patients, regulators, and industry for meaningful discussions. Feedback is encouraged to refine this framework to support FDA approval of AAV gene therapies.

Solid Biosciences Inc. (Nasdaq: SLDB) announced its participation in the Jefferies Gene Therapy/Editing Summit on October 28, 2021, at 2:00 p.m. ET. Co-Founder and CEO Ilan Ganot, along with Chief Scientific Officer Carl Morris, will engage in a fireside chat. Investors can access a live webcast on the company’s investor relations website, with a replay available afterward. The company focuses on developing therapies for Duchenne muscular dystrophy, particularly through its gene therapy candidate, SGT-001.